GME.XETRA

Geratherm Medical AG

GME.XETRA, Germany

Geratherm Medical AG operates as a medical technology company in Germany. It operates through Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems segments. The Healthcare Diagnostic segment provides clinical thermometers; and blood pressure monitors. The Respiratory segment develops and manufactures products primarily for pulmonary and cardiopulmonary function diagnostics. The Medical Warming Systems segment offers MRI-compatible incubators for premature babies under the LMT brand. The Cardio/Stroke segment offers stroke risk analysis products for the detection of atrial fibrillation. The company markets its products through pharmacies, hospitals, and clinics. It exports its products to approximately 60 countries. The company was founded in 1990 and is headquartered in Geschwenda, Germany.

https://www.geratherm.com

Stock Price

€0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GME.XETRA
stock
GME.XETRA

Pre-market: -19.75% DCIK.F DCI Database AG (XETRA) Jan 2026: watch €5.15 support Meyka

Read more →
GME.XETRA
stock
GME.XETRA

Volume spike: QDVN.F iShares MSCI Japan SRI ETF (XETRA) Jan 2026: check upside Meyka

Read more →

Showing 2 of 5

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

STRONG BUY

$

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

8.69

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

0.65

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-0.45 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-0.34 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Medium

9.39 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.33

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Geratherm Medical AG

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2022-09-30

EPS Actual

0.0364

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Strong Deep Value(9.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(6.3)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(2.5)
Momentum
Moderate Momentum(5.5)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Moderate Quality(6)
Value
Undervalued(8)

Income Statement

(Last Updated 2025-06-30)

Revenue

€ 0

Cost Of Revenue

€ 0

Gross Profit

€ 0

Operating Expenses

€ 0

Operating Income

€ 0

Interest Expense

€ 0

Pretax Income

€ 0

Net Income

€ 0

Income Tax Expense

€ 0

EBITDA

€ 0

Total Other Income Expense Net

€ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

€ 0

Short Term Investments

€ 0

Receivables

€ 0

Inventories

€ 0

Total Current Assets

€ 0

Property Plant Equipment

€ 0

Total Assets

€ 0

Payables

€ 0

Short Term Debt

€ 0

Long Term Debt

€ 0

Total Liabilities

€ 0

Equity

€ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

€ 0

Depreciation

€ 0

Change In Working Capital

€ 0

Cash From Operations

€ 0

Capital Expenditures

€ 0

Cash From Investing

€ 0

Cash From Financing

€ 0

Net Change In Cash

€ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.